2025 ASH ISTH NBDF WFH monitoring report Confirms Strength of 2021 VWD Diagnosis and Management Guidelines
Flora Peyvandi, Professor of Internal Medicine-Hemostasis and Thrombosis Unit, University of Milan, former President of ISTH, shared on X:
”2025 ASH ISTH NBDF WFH monitoring report on the 2021 clinical guidelines on the diagnosis and management of von Willebrand disease. None of the reviewed studies would change the direction or strength of the existing guideline recommendations.”
Read the full article here.
A comprehensive review of recent literature assessed whether updates are needed for the ASH ISTH NHF WFH 2021 guidelines on the diagnosis and management of von Willebrand disease (VWD).
Of 432 studies screened for diagnosis and 288 for management, a subset underwent full text review, but none provided evidence strong enough to alter the current recommendations in direction or strength.
As VWD remains the most common inherited bleeding disorder, continued monitoring of emerging data is planned to ensure the guidelines remain current and evidence-based.

Find latest scientific updates on von Willebrand disease featured in Hemostasis Today.
-
Mar 6, 2026, 16:51Priya Reehal: Highlighting The Central Role of Nurses in Cardio-Oncology
-
Mar 6, 2026, 16:50Rainer Kaiser: Blinatumomab Shows Remarkable Response in Multi-Refractory ITP and APS
-
Mar 6, 2026, 16:18Laila Shalabi: Clopidogrel, Aspirin, and the Role of PPIs in Coronary Artery Disease
-
Mar 6, 2026, 16:17Paul McKenzie: The Value of Gene Therapy in Bleeding Disorders
-
Mar 6, 2026, 16:15Basma El Homasany: The ‘Little Brain’ of the Heart and Its Role in Health
-
Mar 6, 2026, 16:14Jamal Rana: Family History and Polygenic Risk for Coronary Heart Disease
-
Mar 6, 2026, 15:43Kristy Ainslie: Breaking Down the Discovery and FDA Approval of Drug Carriers
-
Mar 6, 2026, 15:18Claudio Laudani: Efficacy and Safety of Colchicine for Secondary Prevention in Coronary Artery Disease
-
Mar 6, 2026, 15:09Chris Simon: Persona PLUS Receives FDA Clearance for Patent‑Protected Plasma Apheresis